상세 보기
Treatment Outcomes after Dose-Escalated Moderately Hypofractionated Radiotherapy for Frail Patients with High-Grade Glioma
- Kim, Nalee;
- Shin, Hyunju;
- Lim, Do Hoon;
- Nam, Do-Hyun;
- Lee, Jung-Il;
- ... Seol, Ho Jun;
- ... Kong, Doo-Sik;
- ... Choi, Jung Won;
- ... Chong, Kyuha;
- ... Lee, Won Jae
WEB OF SCIENCE
3SCOPUS
3초록
Simple Summary Historically, frail patients who were older and showed poor performance status have been treated with a total dose of 40-45 Gy in 15 fractions, 34 Gy in 10 fractions, or 25 Gy in 5 fractions. We analyzed the oncologic outcomes after dose-escalated fractionated radiotherapy with a total dose of 56 Gy in 20 fractions for high-grade glioma in frail patients who were older than 70 years or showed poor performance status. This dose-escalated regimen with a total dose of 56 Gy in 20 fractions were comparable equivalent dose to conventional radiotherapy with a total dose 60 Gy in 30 fractions for non-frail patients. We observed survival outcomes outperforming historical data. The median overall survival was 12 months. Also, none of these patients experienced severe treatment-related toxicities. Furthermore, salvage treatment (either systemic therapy or local therapy) after progressive disease significantly improved survival outcomes after recurrence compared to supportive care even in frail patients.Abstract For high-grade glioma (HGG) patients with old age or poor performance status, hypofractionated radiotherapy (hypoRT) in 10-15 fractions is recommended. Also, limited data exist on the impact of salvage treatment after progression in frail patients. We retrospectively analyzed the outcomes of dose-escalated hypoRT in 40 frail HGG patients who were treated with hypoRT between 2013 and 2021. With a median biologically effective dose of 71.7 Gy, a total dose of 56 Gy in 20 fractions was the most frequently used regimen (53.7%). The median age and Karnofsky Performance Status of patients were 74 years and 70, respectively. Most patients (n = 31, 77.5%) were diagnosed with glioblastoma, IDH-wildtype, CNS WHO grade 4. Only 10 (25.0%) patients underwent surgical resection, and 28 (70.0%) patients received concurrent temozolomide during hypoRT. With a median follow-up of 9.7 months, the median overall survival (OS) was 12.2 months. Of the 30 (75.0%) patients with disease progression, only 12 patients received salvage treatment. The OS after progression differed significantly depending on salvage treatment (median OS, 9.6 vs. 4.6 months, p = 0.032). Dose-escalated hypoRT in 20 fractions produced survival outcomes outperforming historical data for frail patients.
키워드
- 제목
- Treatment Outcomes after Dose-Escalated Moderately Hypofractionated Radiotherapy for Frail Patients with High-Grade Glioma
- 저자
- Kim, Nalee; Shin, Hyunju; Lim, Do Hoon; Nam, Do-Hyun; Lee, Jung-Il; Seol, Ho Jun; Kong, Doo-Sik; Choi, Jung Won; Chong, Kyuha; Lee, Won Jae
- 발행일
- 2024-01
- 유형
- Article
- 저널명
- Cancers
- 권
- 16
- 호
- 1
- 언어
- ENG
- 출판사
- Multidisciplinary Digital Publishing Institute (MDPI)
- 발행국가
- 스위스
- ISSN
- E 2072-6694